Charles Bonnet Syndrome: Visual Hallucinations in Vision Loss—Causes, Management, and Reassurance

Charles Bonnet Syndrome: Visual Hallucinations in Vision Loss—Causes, Management, and Reassurance

Charles Bonnet Syndrome (CBS) causes vivid, complex visual hallucinations in people with significant vision loss—most commonly age-related macular degeneration (AMD), glaucoma, or diabetic retinopathy. It is not a psychiatric disorder; the brain generates images to compensate for absent visual input. Prevalence: 10–40% of low-vision patients, often underreported due to stigma.

Hallucination Characteristics

  • Content: Geometric patterns, landscapes, people (often small/lilliputian), animals, buildings, text—typically pleasant or neutral, rarely threatening
  • Visual quality: Detailed, colorful, dynamic; distinct from reality (patient retains insight)
  • Location: Often peripheral or in blind spots (scotomas)
  • Duration: Seconds to minutes; episodes cluster then remit
  • Frequency: Daily to monthly; may persist years
  • Insight preserved: Patients know hallucinations aren't real (key distinction from psychosis/dementia)

Pathophysiology

Deafferentation hypothesis: Visual cortex, deprived of input, becomes hyperexcitable and generates spontaneous activity (release phenomenon). fMRI shows activation in visual association areas during hallucinations. Risk factors: severe vision loss (acuity <20/200), older age, bilateral disease, cognitive reserve, social isolation.

Diagnosis

  1. Confirm significant visual impairment
  2. Hallucinations: visual only (not auditory/tactile), complex, insight intact
  3. Exclude: delirium, dementia, psychiatric illness, medication toxicity (anticholinergics, opioids), metabolic derangements, occipital seizure, migraine aura, peduncular hallucinosis
  4. Neuroimaging if atypical features

Management Strategies

1. Reassurance and Education (Cornerstone)

Explain CBS is a known consequence of vision loss—not mental illness. Normalize; reduce fear/shame. Provide written resources (e.g., Esme's Umbrella, Macular Society).

2. Environmental and Sensory Modifications

  • Improve lighting (reduce shadows that trigger patterns)
  • Increase visual stimulation (audiobooks, tactile activities, social engagement)
  • Eye movements: rapid left-right scanning may interrupt episodes
  • Close eyes/blink deliberately when hallucination starts

3. Optimize Vision

  • Low-vision rehabilitation: magnifiers, CCTV, high-contrast aids
  • Treat underlying eye disease (anti-VEGF for AMD, glaucoma drops, cataract surgery)

4. Medical Therapy (Limited Evidence, Refractory Cases)

  • Cholinesterase inhibitors (donepezil, rivastigmine) – case reports
  • Anticonvulsants (gabapentin, valproate)
  • Atypical antipsychotics (quetiapine, olanzapine) – low dose, cautious; metabolic risks
  • SSRIs if comorbid anxiety/depression

5. Psychosocial Support

  • Support groups (in-person/online)
  • CBT for distress reduction
  • Caregiver education

Prognosis

Benign, self-limited in many. Hallucinations often diminish over 12–18 months as brain adapts. No increased dementia risk. Quality of life improves with validation and coping tools.

Key message: "You are not losing your mind—your brain is filling in the blanks." Early discussion with eye care provider prevents unnecessary neurologic/psychiatric workups.

Genetic Disorders - Related Articles